Polyplus-transfection licenses mammalian transient transfection technology to Kempbio
14 June 2010
US biotechnology services company Kempbio, Inc has signed a license agreement with Strasbourg based Polyplus-transfection SA to use polyethylenimine (PEI) for the transfection of cells used for the production of recombinant proteins.
By signing this license, Kempbio becomes one of Polyplus’
sub-licensees for the use of PEI technology for the expression of
proteins on milligram and gram scales using the human cell line
HEK-293 and other mammalian host cells. The production of
recombinant proteins in human cell lines results in authentic human
post-translational processing providing advantages for the stability
and biological activity of proteins useful in the development of
human therapeutics and diagnostic reagents.
“We are truly delighted to sign this license agreement with Kempbio, a company offering quality cell culture and protein expression services,” said Mark Bloomfield, CEO of Polyplus-transfection. “PEI is clearly the reagent of choice for research into large-scale mammalian transient transfection, and this agreement allows Kempbio to use PEI for its transfection services offering. Our business relationship with Kembio also demonstrates the significant value of our intellectual property rights in the field of PEI-mediated nucleic acid delivery.”